Tsvetelina Pencheva Hoang
About Tsvetelina Pencheva Hoang
Tsvetelina P. Hoang: Vice President, Research & Development
Tsvetelina P. Hoang currently serves as the Vice President of Research & Development. She has a career spanning over 15 years in the field of cancer immunotherapy, where she has contributed significantly to the development of antibody-based and adoptive cell therapies. Her expertise extends to leading various innovative projects and overseeing research teams to push the boundaries of cancer treatment.
Tsvetelina P. Hoang's Experience in Cancer Immunotherapy
Tsvetelina P. Hoang boasts over 15 years of specialized experience in cancer immunotherapy. Her work encompasses a variety of therapeutic approaches, including the development of antibody-based therapies and adoptive cell therapies. At Bellicum Pharmaceuticals, she directed translational research efforts that included the pre-clinical development of T cell receptor (TCR) and chimeric antigen receptor (CAR)-engineered T cell therapy programs. These initiatives aimed to advance innovative treatments for cancer patients.
Academic Background of Tsvetelina P. Hoang
Tsvetelina P. Hoang earned her Ph.D. from Johns Hopkins University, a leading institution in medical research and education. She also holds a combined B.S./M.S. degree with distinction, magna cum laude, from Yale University. Her academic achievements have been recognized through her membership in the prestigious Phi Beta Kappa honor society, as well as being a recipient of a fellowship from the Cancer Research Institute.
Tsvetelina P. Hoang's Tenure at Bellicum Pharmaceuticals
At Bellicum Pharmaceuticals, Tsvetelina P. Hoang functioned as the Director of Translational Research. In this role, she oversaw the pre-clinical development of innovative T cell therapies, specifically targeting T cell receptor (TCR) and chimeric antigen receptor (CAR)-engineered T cells. These projects were instrumental in progressing the company's objectives in the field of adoptive cell therapies for cancer treatment.
Tsvetelina P. Hoang's Research at MD Anderson Cancer Center
Prior to her industry roles, Tsvetelina P. Hoang served as a faculty member at The University of Texas MD Anderson Cancer Center. During her tenure, she focused on the molecular mechanisms of immune checkpoint inhibitors' function. Her research included close collaboration with Dr. James Allison, the 2018 Nobel Laureate in medicine, where they investigated the intricacies of how immune checkpoint inhibitors work to boost the immune system's ability to fight cancer.